Survival analysis and causes of mortality in patients with lupus nephritis
Nephrology Dialysis Transplantation,

Yap DYH et al. – Lupus nephritis is associated with a 6–fold increase in mortality compared with the general population. Lupus patients who develop end–stage renal disease have a 26–fold excess in the risk of death, which is more than twice the risk associated with malignancy or cardiovascular disease in these patients.

Methods
  • The records of all lupus nephritis patients followed in a single centre during 1968–2008 were reviewed.
  • The causes of death were identified, the survival curves constructed and the standardized mortality ratios (SMRs) of potential risk factors were calculated with reference to the local general population.

Results
  • Two hundred and thirty systemic lupus erythematosus patients with history of renal involvement (predominantly Class III/IV lupus nephritis with or without membranous features) were included.
  • The follow–up was 4076.6 person–years (mean 17.7 ± 8.9 years).
  • Twenty–four patients (10.4%) died, and 85% of the deaths occurred after 10 years of follow–up.
  • The 5–, 10–, and 20–year survival rates were 98.6, 98.2 and 90.5%, respectively.
  • The leading causes of death were infection (50.0%), cardiovascular disease (20.8%) and malignancy (12.5%).
  • The renal survival rates at 5, 10 and 20 years were 99.5, 98.0 and 89.7%, respectively.
  • The SMR in patients with renal involvement, end–stage renal disease (ESRD), malignancy or cardiovascular disease was 5.9, 26.1, 12.9 and 13.6, respectively.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Coffee or tea consumption and the risk of rheumatoid arthritis: A meta-analysis Clinical Rheumatology, October 15, 2014    Clinical Article

2 Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye Mayo Clinic, November 19, 2014

3 Homeopathy in the treatment of fibromyalgia- A comprehensive literature-review and meta-analysis Complementary Therapies in Medicine, August 15, 2014    Evidence Based Medicine    Review Article

4 Blood test could prevent medication trial and error for rheumatoid arthritis patients Mayo Clinic, November 18, 2014

5 Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: The TRIO study Osteoporosis International, November 12, 2014    Clinical Article

6 Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial Annals of Rheumatic Diseases, November 10, 2014    Clinical Article

7 New treatments for inflammatory rheumatic disease Immunologic Research, November 17, 2014    Review Article

8 Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study Rheumatology, February 11, 2014    Clinical Article

9 Sustained remission with etanercept tapering in early rheumatoid arthritis New England Journal of Medicine, November 10, 2014    Evidence Based Medicine    Clinical Article

10 The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials American Journal of Medicine, October 6, 2014    Clinical Article

11 Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: An observational cohort study Rheumatology, August 12, 2014    Clinical Article

12 Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? Immunologic Research, November 17, 2014    Review Article    Clinical Article

13 Comparison of the efficacy, adverse effects and cost of zoledronic acid and denosumab in the treatment of osteoporosis Endocrine Practice, November 7, 2014    Review Article

14 Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study Annals of Rheumatic Diseases, November 18, 2014    Clinical Article

15 A double-blind, placebo-controlled, randomized, 12-week, dose-ranging study of VX-509 (decernotinib), an oral selective janus kinase 3 (JAK3) inhibitor, as monotherapy in patients with active rheumatoid arthritis Arthritis & Rheumatism, November 14, 2014    Clinical Article

16 Yearly treatment could slow osteoarthritis Monash University News, September 23, 2014

17 Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study Clinical Rheumatology, February 17, 2014    Clinical Article

18 Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised Phase IIb study Annals of Rheumatic Diseases, August 12, 2014    Clinical Article

19 Drug-associated cutaneous vasculitis: Study of 239 patients from a single referral center The Journal of Rheumatology, September 25, 2014    Clinical Article

20 Study by UCLA scientists reveals new findings about cause of lesions around jaw bone UCLA Health System, November 26, 2014

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore